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Abstract
Secretion of neurotransmitters and neuropeptides is mediated by exocytosis of distinct secretory organelles, synaptic
vesicles (SVs) and dense core vesicles (DCVs) respectively. Relatively little is known about factors that differentially regulate
SV and DCV secretion. Here we identify a novel protein RIC-7 that is required for neuropeptide secretion in Caenorhabditis
elegans. The RIC-7 protein is expressed in all neurons and is localized to presynaptic terminals. Imaging, electrophysiology,
and behavioral analysis of ric-7 mutants indicates that acetylcholine release occurs normally, while neuropeptide release is
significantly decreased. These results suggest that RIC-7 promotes DCV–mediated secretion.
Citation: Hao Y, Hu Z, Sieburth D, Kaplan JM (2012) RIC-7 Promotes Neuropeptide Secretion. PLoS Genet 8(1): e1002464. doi:10.1371/journal.pgen.1002464
Editor: Andrew D. Chisholm, University of California San Diego, United States of America
Received July 8, 2011; Accepted November 18, 2011; Published January 19, 2012
Copyright:  2012 Hao et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by NIH research grant DK80215 (JMK). The funders had no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: kaplan@molbio.mgh.harvard.edu
Introduction
Neurons secrete both neuropeptides and neurotransmitters.
Neurotransmitters, such as acetylcholine (ACh), are secreted by
exocytosis of small clear synaptic vesicles (SVs) whereas neuro-
peptide secretion is mediated by exocytosis of dense core vesicles
(DCVs) [1,2]. The mechanisms leading to DCV and SV exocytosis
are similar in many respects. SVs and DCVs both undergo
physical docking to the plasma membrane, requiring Munc18 and
syntaxin for docking in both cases [3–7]. To become fusion
competent, SVs and DCVs must both undergo a priming reaction,
which is mediated by priming factors (e.g. Munc13 and CAPS)
[8,9]. Exocytosis of SVs and DCVs are both mediated by
assembling complexes between vesicular and plasma membrane
SNARE proteins [10,11]. Finally, calcium-evoked fusion of SVs
and DCVs are mediated by distinct calcium sensors, which are
thought to be different synaptotagmin isoforms [12].
Beyond these similarities, DCVs and SVs exhibit many important
differences.DCVscanbefoundallalongthecellbody,dendritesand
axons of neurons whereas SVs cluster specifically at active zones of
synapses [13]. SVs undergo repeated cycles of exo- and endocytosis
at synapses, whereas neuropeptides are only packaged into nascent
DCVs in the Golgi [14]. Consequently, DCVs cannot undergo local
recycling in axons or dendrites. DCVs release their contents over
long timescales (.50 ms) while SV exocytosis occurs more rapidly
(,20 ms) [13,15]. Exocytosis of SVs can be evoked by single action
potentials while DCV release typically occurs after more prolonged
or repeated depolarizations. These differences imply that different
molecules are involved in SV and DCV secretion.
To date, very few proteins have been found that are specifically
involved in the secretion of one or the other class of vesicles. UNC-
31/CAPS (Calcium-dependent Activator Protein for Secretion) is
proposed to promote priming of DCVs but not SVs [16–18].
However, a subsequent study showed compelling evidence for SV
priming defects in CAPS1 and CAPS2 double knockout mice [19],
implying that CAPS is also required for SV priming. Similarly,
some studies propose that Munc13 primes SVs but not DCVs
[18], while others find Munc13 mutants have exocytosis defects for
both SVs and DCVs [20,21]. C. elegans mutants lacking PKC-1, a
PKCe ortholog, had significant defects in DCV release but little
effect on SV release [20]. Identifying new genes that differentially
regulate SV or DCV release will provide new insights into the
mechanisms underlying these two forms of secretion.
In C. elegans, the acetylcholinesterase inhibitor aldicarb has been
widely used to study neuromuscular signaling in live animals.
Aldicarb treatment causes acetylcholine (ACh) to accumulate in
the synaptic cleft at NMJs, resulting in an acute paralysis of treated
animals. Mutations or RNAi treatments that reduce ACh release
confer resistance to aldicarb-induced paralysis, whereas those that
stimulate ACh secretion enhance aldicarb sensitivity [22,23,24].
We previously showed that neuropeptides also regulate aldicarb
responsiveness [24,25]. Inactivation of genes encoding proneur-
opeptide processing enzymes [for example, egl-3 prohormone
convertase (PC2), egl-21 carboxypeptidase E (CPE), sbt-1 7B2, and
nep-1 neprilysin], proneuropeptides (ins-22, ins-31, flp-1, nlp-12),
neuropeptide receptors (fshr-1) all cause aldicarb resistance
[24,25]. These results suggested that new genes that are required
for DCV secretion could be identified through screens for aldicarb
resistant mutants.
In a screen for mutations that suppress the aldicarb hypersensi-
tivity of dgk-1 diacylglycerol kinase (DAGK) mutants, we isolated a
new allele of the ric-7 gene. Here we show that ric-7 encodes a novel
nematodespecificproteinthatisrequiredforneuropeptidesecretion.
Results
RIC-7 functions in cholinergic neurons for aldicarb
responsiveness
To identify new genes required for neuromuscular function, we
screened for mutations that suppress the aldicarb hypersensitivity
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cantly decreased the aldicarb hypersensitivity of dgk-1 mutants.
The nu447 mutation mapped close to the ric-7 gene, which was
identified in prior screens for aldicarb resistant mutants [22]. We
found that nu447 and ric-7(n2657) both correspond to mutations in
F58E10.1 gene (Figure 1A), hereafter referred to as the ric-7 gene.
The ric-7 locus encodes two isoforms (A and B) that differ only in
their first exon. Orthologs of ric-7 are observed in several other
nematodes, but homologous genes are not detected in other
metazoans. The predicted RIC-7 protein does not contain any
previously described structural domains.
Animals homozygous for nu447 or n2657 were resistant to the
paralytic effects of aldicarb (Figure 1B). To determine whether
RIC-7 functions in motor neurons for aldicarb responsiveness, we
constructed a ric-7 transcriptional reporter. The resulting construct
expressed GFP in many neurons, including both cholinergic and
GABAergic motor neurons (Figure 2A–2B). Transgenes expressing
either RIC-7A or B isoforms in all neurons (with the snb-1
promoter), and those expressing RIC-7B in cholinergic neurons
(with the unc-17 promoter) rescued the aldicarb sensitivity defect of
ric-7 mutants (Figure 1B). By contrast, expressing RIC-7B in
GABAergic neurons (unc-25 promoter) or in muscles (myo-3
promoter) did not rescue the aldicarb phenotype of ric-7 mutants
(Figure 1B). These results suggest that RIC-7 activity is required in
cholinergic neurons for aldicarb responsiveness.
Animals lacking ric-7 also had decreased locomotion rates
(Figure 1C). This locomotion defect was fully rescued by ric-7
transgenes expressed in all neurons (using the snb-1 promoter)
whereas partial rescue was observed with transgenes expressed in
cholinergic or GABAergic neurons (Figure 1C). The morphology
of motor neuron axons and NMJs appeared superficially normal in
ric-7 mutants (Figure 4C and data not shown), suggesting that
these motor defects were unlikely to be caused by changes in
neural development.
RIC-7 is targeted to presynaptic terminals
We expressed GFP-tagged RIC-7 constructs in the cholinergic
DA neurons (using the unc-129 promoter). The RIC-7::GFP protein
was localized in a punctate distribution in both cell bodies and
dorsal cord axons. The majority of RIC-7 puncta co-localized with
an SV marker (mCherry-tagged Endophilin) [26], suggesting that
RIC-7 is targeted to synapses (Figure 2C). We also compared the
distribution of GFP-tagged RIC-7 with a mCherry-tagged neuro-
peptide, NLP-21. Whereas RIC-7 showed partial overlap with
endophilin, nearly complete co-localization was observed with
NLP-21 (Figure 2C). Several results suggest that the co-localization
of RIC-7 with DCVs was not mediated by physical association of
RIC-7 with nascent DCVs. First, RIC-7 synaptic localization was
notdisrupted in unc-104 mutants (Figure 2D), whichlack the KIF1A
motor responsible for anterograde transport of SVs and DCVs.
Thus, RIC-7 is not co-transported to synapses with immature
Figure 1. Aldicarb response and locomotion defects in ric-7
mutants. (A) A schematic illustrating the ric-7 gene structure is shown.
Deleted regions (bar), point mutations (arrows), and the site utilized for
GFP/mCherry tagging are indicated. (B–C) Aldicarb-induced paralysis (B)
and locomotion rate (C) are compared for the indicated genotypes. The
number of trials (,20 animals/trial, B) or the number of animals
analyzed (C) are indicated for each genotype. For rescue experiments,
ric-7 transgenes are indicated as follows: ACh (unc-17 promoter), GABA
(unc-25 promoter), pan-neuron (snb-1 promoter), muscle (myo-3
promoter). Values that differ significantly from wild type (**, p,0.001,
Student’s t-test) and from ric-7 mutants (#,p ,0.01; ##,p ,0.001,
Student’s t-test) are indicated. Error bars indicate SEM.
doi:10.1371/journal.pgen.1002464.g001
Author Summary
Neuropeptides produce prolonged changes in circuit
activity that are associated with changes in behavioral
states (e.g. mood or appetite); consequently, there is great
interest in identifying molecules that are required for
neuropeptide secretion. Here we show that a novel
neuronal protein RIC-7 promotes neuropeptide secretion
in C. elegans but has only subtle effects on neurotrans-
mitter secretion. RIC-7 is conserved in several other
nematodes; however, homologous proteins are not found
in other sequenced genomes. These results suggest that
the machinery responsible for neuropeptide secretion
evolved more recently than factors that are required for
both neurotransmitter and neuropeptide secretion.
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sequence and GFP-tagged RIC-7 did not produce fluorescence in
coelomocytes, both of which indicate that RIC-7 is not translocated
into SVs or DCVs (data not shown). These results support the idea
that RIC-7functions inthe cytoplasmat presynapsesand could play
a relatively direct role in regulating SV or DCV secretion.
Muscle responsiveness to ACh and GABA is unaltered in
ric-7 mutants
We did several experiments to test the effects of RIC-7 on the
responsiveness of body muscles to neuromuscular agonists
(Figure 3). First, the sensitivity of ric-7 mutants to the paralytic
effects of the nicotinic agonist levamisole was similar to that of wild
type controls (Figure 3A). Second, we recorded body wall muscle
currents evoked by application of ACh or the GABA agonist
muscimol. In both cases, the amplitude of agonist-evoked current
in ric-7 mutant body muscles was not significantly different from
that observed in wild type controls (Figure 3B). Third, the
fluorescent intensities of GFP-tagged ACR-16 ACh receptor
(Figure 3C) and UNC-49 GABAA receptor (Figure 3D) puncta
in the nerve cord were unaltered in ric-7 mutants, indicating that
the abundance of post-synaptic receptors at NMJs was normal.
Thus, the effect of RIC-7 on aldicarb responsiveness is unlikely to
be caused by altered agonist responsiveness of body muscles.
ACh release occurs normally in ric-7 mutants
The aldicarb resistance phenotype observed in ric-7 mutants
could be caused by decreased ACh secretion, increased GABA
secretion, or decreased neuropeptide secretion, as aldicarb
resistance would be expected in all three scenarios [25,27,28].
To assay ACh secretion more directly, we recorded excitatory
post-synaptic currents (EPSCs) from body muscles (Figure 4). We
found that the rate and amplitude of endogenous EPSCs, i.e. SV
fusions evoked by the endogenous activity of motor neurons, in ric-
7 mutants were similar to those found in wild type animals
(Figure 4A). In addition, the amplitude of stimulus-evoked EPSCs
in ric-7 mutants was not significantly different from wild type
(Figure 4B). Therefore, baseline ACh secretion occurs normally at
cholinergic NMJs in ric-7 mutants.
To further analyze the cholinergic NMJs, we examined the
distribution of GFP-tagged Synaptobrevin (GFP::SNB-1) in motor
neurons. Changes in the distribution of GFP::SNB-1 are
correlated with changes in SV exo- and endocytosis. SNB-1
puncta intensity is correlated with the number of SVs at
Figure 2. Expression pattern of RIC-7. (A) The ric-7 promoter expresses nuclear localized Cherry (HIS-24::wCherry) primarily in the nervous system
of an adult worm. Anterior is left; ventral is up. The asterisk indicates fluorescence encoded by a co-injection marker. (B) The ric-7 promoter is
expressed in cholinergic (top panel) and GABAergic (bottom panel) motor neurons in the ventral cord. Cell bodies of cholinergic (unc-17 promoter)
and GABAergic (unc-30 promoter) neurons were identified by expression of the indicated GFP reporter constructs. (C) Distribution of RIC-7, a synaptic
vesicle marker (UNC-57 Endophilin) (top panel), and a DCV marker (NLP-21) (bottom panel) are compared in the dorsal cord axons of cholinergic
motor neurons. (D) Distribution of RIC-7::GFP in cholinergic motor neurons of unc-104 KIF1A mutants. Cell bodies (arrow) and ventral cord processes
(arrow heads) are indicated.
doi:10.1371/journal.pgen.1002464.g002
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of synapse density. Neither the fluorescent intensity nor the density
of SNB-1 puncta in the cholinergic axons of ric-7 mutants were
significantly different from that observed in wild type controls
(Figure 4C). Taken together, these results suggest that defects in
baseline ACh secretion are unlikely to account for the aldicarb
resistance of ric-7 mutants.
RIC-7 promotes neuropeptide secretion
Aldicarb resistance could also be caused by defects in
neuropeptide signaling [25]; therefore, we next examined ric-7
mutants for changes in neuropeptide signaling. First, we analyzed
the aldicarb responsiveness of ric-7 double mutants containing
mutations in neuropeptide signaling components. If changes in
neuropeptide action contribute to RIC-7’s effects on aldicarb
responsiveness, then we would expect that ric-7 mutations would
occlude the effect of neuropeptide signaling mutations on aldicarb
resistance. Consistent with this idea, ric-7 double mutants carrying
mutations in either of two proneuropeptide processing enzymes
(egl-21 CPE and egl-3 PC2) had aldicarb resistance that was similar
to that observed in ric-7 single mutants (Figure 5). These results
support the idea that RIC-7 regulation of neuropeptide secretion
Figure 3. Body muscle responses to ACh and GABA are unaltered in ric-7 mutants. (A) Time course of levamisole (200 mM) induced
paralysis is shown for wild type and ric-7(nu447) adults. Three trials (,20 animals/trial) were performed for each genotype. (B) ACh (top) and
Muscimol (bottom)-activated currents were recorded from body wall muscles of ric-7 and wild type adults. Representative responses (left) and
summary data (right) are shown. Wild type and ric-7 mutant responses were not significantly different. (C–D) Representative images (above) and
summary data (below) are shown for ACR-16::GFP (C) and UNC-49::GFP (D) expressed in body muscles of wild type and ric-7 adults (using the myo-3
promoter). No significant differences were observed. The number of animals analyzed is indicated for each genotype (panels B–D). Error bars indicate
SEM.
doi:10.1371/journal.pgen.1002464.g003
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responsiveness.
To further address the role of RIC-7 in neuropeptide secretion,
we analyzed the secretion of YFP-tagged neuropeptides (Figure 6).
For this analysis, we selected two proneuropeptides, NLP-21 and
INS-22, which encode FMRFamide related peptides (FaRPs) and
an insulin-like growth factor, respectively. When NLP-21::YFP or
INS-22::YFP are expressed in the cholinergic DA motor neurons
(using the unc-129 promoter), puntate fluorescence is detected in
dorsal cord axons and in coelomocytes (Figure 6A and 6C). We
previously showed that the axonal puncta fluorescence corre-
sponds to secretory granules containing these proneuropeptides
while the coelomocyte fluorescence corresponds to secreted
neuropeptides that have been endocytosed [20,30]. In ric-7
mutants, NLP-21 coelomocyte fluorescence was significantly
decreased (,50%, p,0.001) (Figure 6C–6D) whereas the NLP-
21 puncta fluorescence intensity in dorsal cord axons was
significantly increased (.2-fold, p,0.001) (Figure 6A–6B). The
coelomocyte and axonal NLP-21 fluorescence defects were both
rescued by ric-7 transgenes expressed in the DA neurons. Similar
Figure 4. Baseline ACh release is unaltered in ric-7 mutants. Endogenous EPSCs (A) and stimulus-evoked EPSCs (B) were recorded from body
wall muscles of wild type and ric-7(nu447) adults. Representative traces of endogenous EPSCs (A), averaged traces of stimulus-evoked responses (B),
and summary data for both are shown. The number of animals analyzed is indicated for each genotype. No significant differences were observed. (C)
Representative images (left) and summary data (right) are shown for GFP-tagged SNB-1 in dorsal cord axons of cholinergic motor neurons (expressed
with the unc-129 promoter) in wild type and ric-7 adults. The number of animals analyzed is indicated for each genotype. No significant differences
were observed. Error bars indicate SEM.
doi:10.1371/journal.pgen.1002464.g004
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cence was observed for a second proneuropeptide (INS-22) in ric-7
mutants (Figure 6). These results suggest that ric-7 mutants have
decreased neuropeptide secretion, which results in an accumula-
tion of DCVs in motor axons.
RIC-7 is required for NLP-12–mediated enhancement of
ACh release
Inactivation of NLP-21 and INS-22 by RNAi does not produce
strong locomotion or aldicarb resistance defects [24]; consequent-
ly, NLP-21 and INS-22 are unlikely to be the only neuropeptides
involved in the Ric-7 locomotion and aldicarb-resistance pheno-
types. We recently identified NLP-12 as a neuropeptide that plays
a critical role in regulating both locomotion rate and aldicarb-
induced paralysis [31]. NLP-12 is expressed in a proprioceptive
neuron (DVA) that is activated by body muscle contractions
[32,33]. If Ric-7 aldicarb resistance and locomotion defects are
caused by decreased neuropeptide release, we would expect that
NLP-12 secretion from DVA would be diminished in ric-7
mutants. We did several experiments to test this idea. First, we
analyzed the effect of ric-7 mutations on secretion of YFP-tagged
NLP-12 from DVA neurons (Figure 7A–7B). In wild type animals,
aldicarb treatment significantly decreased NLP-12 puncta fluores-
cence in DVA axons (indicating increased NLP-12 secretion),
which is most likely caused by activation of DVA stretch receptors
by muscle contraction [31]. By contrast, in ric-7 mutants, aldicarb
had no effect on NLP-12 puncta fluorescence, indicating that
RIC-7 is required for aldicarb-evoked NLP-12 secretion.
Second, if the NLP-12 secretion defect contributes to the Ric-7
aldicarb resistance phenotype, we would expect that RIC-7
expression in DVA neurons would be sufficient to alter aldicarb
responsiveness. Consistent with this idea, the aldicarb responsive-
ness of ric-7 mutants was significantly improved by transgenes
expressing RIC-7 in DVA neurons (Figure 7C). This result is
consistent with the preceding rescue data (Figure 1B) because the
unc-17 promoter (which also rescued the Ric-7 aldicarb defect) is
expressed in DVA neurons (data not shown). Collectively, these
data suggest that proper aldicarb responsiveness requires RIC-7
function in multiple neuron classes because RIC-7 expression in a
single cholinergic neuron (DVA) produced partial rescue of the
aldicarb defect whereas complete rescue was obtained following
expression in all cholinergic neurons (with the unc-17 promoter)
(Figure 1B).
Third, we analyzed evoked ACh release following aldicarb
treatment. In wild type animals, a 60 minute pre-treatment with
aldicarb significantly increases the total synaptic charge occurring
during an evoked response (Figure 7D–7E) [31]. This effect is
eliminated in egl-3 PC2 mutants and in nlp-12 mutants [31]. Thus,
aldicarb enhancement of evoked ACh release can be utilized to
assess changes in endogenous NLP-12 secretion. Aldicarb’s effect
on evoked ACh release was also eliminated in ric-7 mutants
(Figure 7D–7E). Collectively, these results strongly support the
idea that RIC-7 acts in DVA neurons to promote secretion of
endogenous NLP-12, and that this contributes to the Ric-7
aldicarb-resistance defect.
GABA transmission is altered in ric-7 mutants
Changes in GABA secretion could also contribute to the
aldicarb resistance observed in ric-7 mutants [22,27,28]. Consis-
tent with this idea, ric-7 mutants had defects in defecation behavior
that are similar to those observed in mutants with decreased
GABA transmission (Figure 8A). Contraction of the intestinal
muscles during defecation (i.e. the expulsion step of the defecation
motor program) is mediated by excitatory GABAergic input from
defecation motor neurons [34]. We found that ric-7 mutants had a
significant expulsion defect, which was rescued by ric-7 transgenes
expressed in GABA neurons (Figure 8A). These results suggest that
ric-7 mutants have a presynaptic defect at GABAergic NMJs
involved in defecation.
To assay GABA release at ventral cord NMJs (which are
involved in locomotion), we recorded inhibitory post-synaptic
currents (IPSCs) from body muscles (Figure 8B). We found that ric-
7 mutants had a wild type IPSC rate, while IPSC amplitudes were
significantly increased (,30%, p,0.001). These results suggest
that GABA secretion still occurs in ric-7 mutants, albeit in a subtly
altered form. Changes in IPSC amplitudes are often caused by
changes in post-synaptic sensitivity, e.g. by changing GABA
receptor abundance. However, neither the current evoked by
applying an exogenous GABA agonist nor the abundance of GFP-
tagged UNC-49 GABA-A receptors were altered in ric-7 mutants,
suggesting that a post-synaptic defect was unlikely to account for
the altered IPSC amplitude (Figure 3B, 3D). Consistent with a pre-
synaptic defect, the distribution of GFP-tagged SNB-1 was altered
in GABAergic neurons of ric-7 mutants. Although SNB-1 puncta
intensity was unaltered, puncta were significantly wider (23%
wider, p,0.001) and diffuse SNB-1 axon fluorescence was
significantly increased in ric-7 mutants (Figure 8C). Finally, the
IPSC and SNB-1 defects were both rescued by transgenes
expressing RIC-7 in GABAergic motor neurons (Figure 8B–8C).
Collectively, these results support the idea that ric-7 mutants have
a pre-synaptic defect that increases GABA secretion, perhaps by
increasing the amount of GABA packaged into each SV. Rescue of
the IPSC defect (with ric-7 transgenes expressed in GABA neurons)
failed to rescue the ric-7 aldicarb defect and weakly rescued the
locomotion defect implying that the latter were not caused by
altered GABA secretion (Figure 1C).
Mutations disrupting neuropeptide signaling exhibit defecation
defects similar to ric-7 mutants [25,35]. Prompted by these results,
we wondered if the Ric-7 defecation and IPSC defects are caused
by the neuropeptide secretion defect. In this scenario, we would
expect that ric-7 mutations and mutations that impair proneur-
Figure 5. Neuropeptide processing mutations and ric-7 muta-
tions do not have additive effects on aldicarb responses. The
paralytic response to aldicarb treatment was analyzed in strains
containing mutations that inactivate pro-neuropeptide processing
enzymes (egl-3 PC2 and egl-21 CPE), or those inactivating RIC-7. The
number of trials (,20 animals/trial) is shown for each genotype. Values
that differ significantly from wild type (*, p,0.01; **, p,0.001, Students
t-test) are indicated. Error bars indicate SEM. Values that are not
significantly different are indicated (ns).
doi:10.1371/journal.pgen.1002464.g005
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behavior in double mutants. Contrary to this idea, the defecation
defects observed in ric-7; egl-21 double mutants were significantly
worse than those observed in either single mutant (Figure 8A). In
addition, IPSC amplitudes were unaltered in egl-3; egl-21 doubles
mutants (Figure S1), suggesting that decreased neuropeptide
secretion is also unlikely to explain the Ric-7 IPSC defect. These
results indicate that RIC-7 cell-autonomously regulates two forms
of secretion, promoting neuropeptide secretion and inhibiting
GABA secretion.
Discussion
Communication between neurons and their targets relies on two
classes of neurosecretory vesicles, synaptic vesicles (SVs) and
dense-core vesicles (DCVs). The mechanisms governing SV and
Figure 6. RIC-7 promotes neuropeptide release. YFP-tagged NLP-21 and INS-22 were expressed in cholinergic motor neurons using the unc-129
promoter. Representative images (A) and summary data (B) are shown for NLP-21 (top) and INS-22 (bottom) fluorescence in dorsal cord axons of the
indicated genotypes. The number of animals analyzed is indicated for each genotype. (C–D) Representative images (C) and summary data (D) are
shown for NLP-21 and INS-22 fluorescence in coelomocytes of the indicated genotypes. The number of animals analyzed is indicated for each
genotype. Values that differ significantly from wild type (**, p,0.001, ***, p,0.0001 Students t-test) and from ric-7 mutants (#,p ,0.01,
##,p ,0.001, Students t-test) are indicated. Error bars indicate SEM. For rescue experiments, ric-7 transgenes are as follows: pan-neuron (snb-1
promoter), DA neuron (unc-129 promoter).
doi:10.1371/journal.pgen.1002464.g006
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proteins, SNARE binding proteins, and calcium sensors). Despite
these similarities, SV and DCV mediated secretion also have
significant differences [1], which imply that some proteins will be
selectively utilized in one or the other process. Because
neuropeptides have dramatic effects on personality, behavior,
and metabolism, there is significant interest in identifying
molecules that selectively promote DCV secretion. Here we
identify RIC-7 as a novel protein that is required for DCV
secretion but has relatively subtle effects on SV secretion. Below
we discuss the implications of these findings.
The ric-7 gene was identified in a screen for mutations
conferring resistance to aldicarb induced paralysis. As RIC-7
lacks identified structural or functional motifs, the mechanisms
underlying this behavioral defect were unclear. In principle,
aldicarb resistance could arise from several alternative mecha-
nisms, including: altered muscle responsiveness to ACh or GABA,
decreased excitatory input from cholinergic motor neurons,
increased hyperpolarizing input from GABA motor neurons, or
decreased neuropeptide signaling. Our results strongly support the
idea that Ric-7 aldicarb and locomotion defects arise from
disruption of neuropeptide secretion.
Several results suggest that RIC-7 does not regulate muscle
sensitivity to neuromuscular agonists. The currents evoked by
applying exogenous ACh and GABA to body muscles, and the
expression of nicotinic and GABA receptors in body muscles were
both unaffected in ric-7 mutants. Furthermore, ric-7 aldicarb and
locomotion defects were not corrected by transgenes expressing
RIC-7 in body muscles, whereas rescue was observed for
transgenes expressed in cholinergic neurons. Thus, RIC-7 neither
acts in body muscles, nor regulates muscle sensitivity to agonists.
Other results indicate that RIC-7 is not required for baseline
ACh secretion. In cholinergic motor neurons, the SV protein
SNB-1 neither accumulated in synaptic puncta nor in the axonal
membrane (as would occur in exocytosis and endocytosis mutants,
respectively). The rate, amplitude, and kinetics of endogenous and
evoked EPSCs were unaltered in ric-7 mutants. Thus, although
RIC-7 expression in cholinergic neurons rescued the aldicarb and
locomotion defects of ric-7 mutants, these defects are unlikely to
arise from decreased baseline ACh secretion.
Figure 7. NLP-12 secretion is decreased in ric-7 mutants. (A) YFP-tagged NLP-12 was expressed in DVA neurons (using the nlp-12 promoter).
Representative images (A) and summary data (B) are shown for NLP-12 puncta fluorescence in the indicated genotypes. The number of animals
analyzed is indicated for each genotype. (C) Aldicarb-induced paralysis was quantified for the indicated genotypes. The number of trials (,20
animals/trial) is indicated for each genotype. (D–E) Stimulus evoked EPSCs were recorded from adult body wall muscles of the indicated genotypes.
Recordings were done after a 60 minute aldicarb pre-treatment (gray) or in untreated controls (black). Averaged evoked responses (D) and summary
data (E) are shown. The number of animals analyzed is indicated for each genotype. Values that differ significantly from wild type (**, p,0.001,
***, p,0.0001, Students t-test) and from ric-7 mutants (##,p ,0.001, ###,p ,0.0001 Students t-test) are indicated. Error bars indicate SEM. For
rescue experiments, ric-7 transgenes are as follows: DVA (nlp-12 promoter).
doi:10.1371/journal.pgen.1002464.g007
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PLoS Genetics | www.plosgenetics.org 8 January 2012 | Volume 8 | Issue 1 | e1002464Figure 8. Analysis of GABA transmission in ric-7 mutants. (A) Intestinal muscle contractions during the defecation motor program (quantified
as expulsions/pBoc) were analyzed in the indicated genotypes. (B) Endogenous IPSCs were recorded from adult body wall muscles of the indicated
genotypes. Representative traces (left), and summary data (right) are shown. The number of animals analyzed is indicated for each genotype. (C)
Representative images (left) and summary data (right) for GFP::SNB-1 (expressed by the unc-25 promoter) in dorsal cord axons of the indicated
genotypes. The number of animals analyzed is indicated for each genotype. Values that differ significantly from wild type (**, p,0.001, ***, p,0.0001
Students t-test) and from ric-7 mutants (#,p ,0.05, ##,p ,0.001, ###,p ,0.0001 Students t-test) are indicated. Error bars indicate SEM. For rescue
experiments, ric-7 transgenes are as follows: ACh (unc-17 promoter), GABA (unc-47 promoter), pan-neuron (snb-1 promoter), intestine (vha-6
promoter).
doi:10.1371/journal.pgen.1002464.g008
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PLoS Genetics | www.plosgenetics.org 9 January 2012 | Volume 8 | Issue 1 | e1002464In GABA neurons, ric-7 mutants had a presynaptic defect that
led to an apparent increase in GABA secretion. This presynaptic
defect was manifest by an increase in amplitude of endogenous
IPSCs in ric-7 mutants, while the IPSC rate was unaltered.
Changes in IPSC amplitudes are often caused by changes in post-
synaptic sensitivity, e.g. by changing GABA receptor abundance.
However, neither the current evoked by applying an exogenous
GABA agonist nor the abundance of GFP-tagged UNC-49
GABA-A receptors were altered in ric-7 mutants, suggesting that
a post-synaptic defect was unlikely to account for the altered IPSC
amplitude. Consistent with a pre-synaptic defect, SNB-1 axonal
fluorescence was significantly increased in ric-7 mutant GABA
motor neurons. The defecation, IPSC, and SNB-1 defects were all
rescued by transgenes expressing RIC-7 in GABAergic motor
neurons. Collectively, these results support the idea that ric-7
mutants have a pre-synaptic defect that increases GABA secretion.
Rescue of the IPSC defect did not correlate with rescue of ric-7
aldicarb and locomotion defects, implying that the latter were not
caused by altered GABA secretion. In principle, the IPSC defect
could cause the Ric-7 defecation defect, for example if increased
GABA secretion causes constitutive excitation of the intestinal
muscles. Double mutant analysis suggests that decreased neuro-
peptide secretion is unlikely to account for the Ric-7 IPSC and
defecation defects. Consequently, our results are most consistent
with the idea that RIC-7 has direct cell autonomous effects on two
forms of secretion, promoting neuropeptide secretion and
inhibiting GABA secretion. Several other proteins are known to
have distinct effects on different neurotransmitter systems. Mouse
Munc13-1 knockouts drastically reduce glutamatergic transmission
yet have little effect on GABA release [36]. Mouse ELKS2
knockouts have increased GABA release but unaltered glutamate
release [37]. Finally, complexin promotes evoked release but
inhibits tonic/spontaneous release [38,39].
Several results suggest that the effects of RIC-7 on aldicarb
sensitivity were caused by changes in neuropeptide secretion. First,
mutations preventing neuropeptide processing (egl-21 CPE, egl-3
PC2) and ric-7 mutations did not have additive effects on aldicarb
responsiveness in double mutants. Second, ric-7 mutants had
greatly decreased secretion of YFP-tagged neuropeptides (NLP-21
and INS-22) from cholinergic motor neurons. Third, mCherry-
tagged RIC-7 co-localized extensively with a DCV marker (NLP-
21), implying that RIC-7 could play a relatively direct role in
regulating neuropeptide release. Fourth, ric-7 mutants have
decreased aldicarb-evoked secretion of NLP-12 from DVA
neurons and lack aldicarb-induced potentiation of evoked ACh
release (which is mediated by endogenous NLP-12). And fifth,
restoring RIC-7 expression in DVA neurons was sufficient to
partially rescue the Ric-7 aldicarb-resistance defect. Taken
together, these results strongly support the idea that RIC-7
promotes secretion of endogenous neuropeptides, and that this
function plays an important role in the Ric-7 aldicarb resistance
and locomotion defects. The Ric-7 aldicarb resistance and
locomotion defects are more severe than those observed in
mutants lacking NLP-12 or those lacking EGL-3 PC2, indicating
that additional RIC-7 functions also contribute to these pheno-
types. These additional functions could include promoting
secretion of other neuropeptides or novel RIC-7 functions that
are not yet defined.
What aspect of DCV secretion is regulated by RIC-7?
Decreased neuropeptide secretion in ric-7 mutants could reflect
changes in any aspect of DCV biogenesis, transport, docking,
priming, calcium-triggering, or fusion. Several results suggest that
RIC-7 is not packaged into DCVs, and consequently cannot play a
role in pro-neuropeptide processing. RIC-7 lacks a predicted
signal peptide sequence, GFP-tagged RIC-7 is not secreted, and
RIC-7 delivery to axons is not prevented in unc-104 KIF1A
mutants. Collectively, these results suggest RIC-7 is cytoplasmic,
and thus cannot play a direct role in neuropeptide processing.
DCV biogenesis and transport also occur normally in ric-7
mutants, as neuropeptide fluorescence in motor axons was
increased rather than decreased. These results suggest that RIC-
7 regulates a step that occurs after DCV transport. Given the
prominent colocalization of RIC-7 and DCV markers in axons, we
speculate the RIC-7 could identify DCV release sites. Because the
sequence of RIC-7 does not provide any clues as to its biochemical
function, further experiments will be required to determine a more
precise function for RIC-7. Understanding the mechanisms
underlying RIC-7’s functions will undoubtedly shed light on how
DCVs assume their unique properties.
The mechanisms governing SV and DCV secretion share many
properties, including: SNARE proteins, SNARE binding proteins
(e.g. Munc13, Munc18, and CAPS), and calcium sensors (e.g.
Synaptotagmin) [40]. These shared mechanisms are highly
conserved across eukaryotic phylogeny, suggesting that these core
exocytosis components comprise an ancient process. By contrast,
RIC-7 orthologs are observed in other nematodes but homologous
genes are not detected in other sequenced genomes. Interestingly,
other putative DCV secretion factors have similar patterns of
conservation. For example, the Rab27 effector granuphilin is
conserved in mammals and flies but not in C. elegans, while a
second Rab27 effector melanophilin is present in mammals but
absent in flies and worms. These results suggest that the
mechanisms distinguishing SV and DCV secretion evolved more
recently than the more ancient shared secretion factors.
Materials and Methods
C. elegans strains and drug assays
Strains were maintained at 20uC as described [41]. The wild-
type reference strain was N2 Bristol. Descriptions of allele lesions
can be found at http://www.wormbase.org. The mutant strains
used were: LGIV, egl-21(n476); LGV, egl-3(nr2090), ric-7 (nu447),
ric-7(n2657). Acute aldicarb and levamisole assays were performed
blind in triplicate on young adult worms as described [42]. The
aldicarb (Chem Services) concentrations used ranged from 1 to
2 mM, the levamisole (Sigma) concentration was 200 mM.
Locomotion was measured by transferring adults to plates
containing fresh (16 h) lawns of HB101 bacteria, letting the
worms recover for 30 min and counting the number of body bends
of active worms in a 3 min interval.
ric-7 mapping and cloning
ric-7(nu447) was isolated in an EMS screen for suppressors of the
aldicarb hypersensitive phenotype of dgk-1(nu62) mutants (D.S.
and J.K., unpublished data). nu447 was mapped by small
nucleotide polymorphism (SNP) mapping, based on its aldicarb
resistance phenotype. Analysis of 16 nu447/CB4856 recombinants
mapped nu447 to LGV, map unit 5,6; Another 62 clones further
positioned nu447 to 5.86,6.00 m.u. Seven predicted genes were
found in this interval with three of them previously characterized.
Sequencing revealed that ric-7(nu447) contained a 830C/T
(A277V) point mutation plus a 32 bp deletion (nucleotides 910–
941) in F58E10.1b cDNA that shifts the reading frame, leading to
a truncated RIC-7 protein that contains 305 amino acids. ric-
7(n2657) contained a 621G/A (W207Stop) nonsense mutation in
F58E10.1b cDNA. nu447 was backcrossed six times and used for
most phenotypic analysis in this study.
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All quantitative imaging was done using a Olympus PlanAPO
10061.4 NA objective and an ORCA100 CCD camera
(Hamamatsu). Worms were immobilized with 30 mg/ml BDM
(Sigma). Image stacks were captured and maximum intensity
projections were obtained using Metamorph 7.1 software
(Molecular Devices). GFP fluorescence was normalized to the
absolute mean fluorescence of 0.5 mm FluoSphere beads
(Molecular Probes). For dorsal cord imaging, young adult worms,
in which the dorsal cords were oriented toward the objective, were
imaged in the region midway between the posterior gonad bend at
the tail. Line scans of dorsal cord fluorescence were analyzed in
Igor Pro (WaveMetrics) using custom-written software [43,44]. For
coelomocyte imaging, the posterior coelomocyte was imaged in
young adults [20]. Image stacks were captured and maximum
intensity projections were obtained using Metamorph 7.1 software
(Molecular Devices). For quantitation, the five brightest vesicles
were analyzed for each coelomocyte and the mean fluorescence
for each vesicle was logged. For each worm, coelomocyte
fluorescence was calculated as the mean of the vesicle values in
that animal. All p-values indicated were based on student t-tests.
Confocal images were taken using the Olympus FV1000
confocal microscope. Image stacks were captured, and maximum
intensity projections were obtained using Metamorph 7.1 software
(Universal Imaging).
Electrophysiology
Electrophysiology was done on dissected adults as previously
described [45]. All recording conditions were as described
previously [20]. For comparing average electrophysiological
values, statistical significance was determined using the Mann-
Whitney test or student’s t test.
RIC-7 constructs and transgenes
Transgenic strains were generated by injecting either wild type
or ric-7(nu447) mutants with the expression construct (10–25 ng/
ml) mixed with the co-injection markers, KP#1338 (pttx-3::GFP),
KP#1480 (pmyo-2::NLS-mCherry)o rK P #1106 (pmyo-2::NLS-GFP),
each at 10 ng/ml, using standard methods [46]. The co-
localization experiments were done by co-injecting KP#1684
(pric-7::his-24 cDNA::wcherry) with KP#1685 (punc-30::NLS-GFP)o r
with KP#1686 (punc-17::NLS-GFP), respectively; or by injecting
KP#1687 (punc-129::RIC-7 cDNA::GFP) into nuIs252 (Punc-
129::mchry::PaGFP::unc-57), or into nuIs470 (punc-129::NLP-
21::mCherry), respectively, all at a concentration of 25 ng/ml each.
All constructs except KP#1684 were derivatives of pPD49.26
[47].
Two RIC-7 constructs rescued the ric-7(nu447) mutant aldicarb
defect: KP#1680 (psnb-1::RIC-7), and KP#1681 (punc-17::RIC-7).
Two RIC-7 constructs did not rescue the ric-7(nu447) mutant
aldicarb defect: KP #1682(punc-25::RIC-7), and KP#1683(pmyo-
3::RIC-7). All four constructs used F58E10.1b cDNA cloned with
NheI and KpnI sites.
The previously reported lines used for imaging experiments
described are nuIs152 (punc-129::GFP::SNB-1), nuIs183 (punc-
129::NLP-21::VENUS), nuIs195 (punc-129::INS-22::VENUS) [20,24],
nuIs283 (pmyo-3::UNC-49::GFP) (J. Bai and J.K., unpublished),
nuIs299 (pmyo-3::ACR-16::GFP) [48], nuIs444 (pnlp-12::NLP-12::VE-
NUS) [31] and nuIs376 (punc-25::SNB-1::GFP).
Supporting Information
Figure S1 IPSCs are not altered in neuropeptide processing
mutants. Endogenous IPSCs were recorded from adult body wall
muscles of the indicated genotypes. Representative traces (A), and
summary data (B) are shown. The number of animals analyzed is
indicated for each genotype. Error bars indicate SEM. No
significant differences were observed.
(TIF)
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